Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | PNP | P00491 | 2/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.42 |
| ▸ | PDE4A | P27815 | 6/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27842808 | 0.85 | PDE4A (0.53) | DPP4PNPADORA2APDE4AADORA2B | |
| SCHEMBL667797 | 0.85 | PDE4A (0.60) | ADORA2APDE4AADORA2BPDE4BPDE4C | |
| SCHEMBL6272735 | 0.83 | PDE4A (0.59) | ADORA2APDE4AADORA2BPDE4BPDE4C | |
| SCHEMBL874737 | 0.82 | ADORA2A (0.56) | DPP4PNPADORA2APDE4AADORA2B | |
| SCHEMBL28071828 | 0.82 | PNP (0.45) | DPP4PNPADORA2APDE4AADORA2B | |
| SCHEMBL1047660 | 0.82 | PNP (0.45) | DPP4PNPADORA2APDE4AADORA2B | |
| SCHEMBL28305222 | 0.82 | PDE4A (0.56) | DPP4PNPADORA2APDE4AADORA2B | |
| SCHEMBL8522275 | 0.82 | ADORA2B (0.61) | ADORA2APDE4AADORA2BPDE4BPDE4C | |
| SCHEMBL17186421 | 0.81 | CDK2 (0.43) | DPP4PNPADORA2APDE4AADORA2B | |
| SCHEMBL8536009 | 0.81 | ADORA2B (0.64) | ADORA2APDE4AADORA2BPDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160022605-A1 | METHODS FOR REDUCING MICROSATELLITE INSTABILITY INDUCED BY CHEMOTHERAPY AND METHODS FOR SCREENING ANTIOXIDANTS THAT SUPPRESS DRUG-INDUCED MICROSATELLITE INSTABILITY WHILE ENHANCING THE CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | CHANG CHRISTINA LING (TW) | 2016-01-28 | — | — | US | disclosed |
| CN-102276610-B | Method for preparing N7-guanine alkylate | UNIV BEIJING TECHNOLOGY | 2013-01-09 | — | — | CN | disclosed |
| CN-102276610-A | Method for preparing N7-guanine alkylate | — | 2011-12-14 | — | — | CN | disclosed |
| EP-0910246-B1 | USE OF MUTANT ALKYLTRANSFERASES FOR GENE THERAPY TO PROTECT FROM TOXICITY OF THERAPEUTIC ALKYLATING AGENTS | PENN STATE RES FOUND (US) | 2010-08-18 | — | — | EP | disclosed |
| CN-100355886-C | nucleotide chain modification method | MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) | 2007-12-19 | — | — | CN | disclosed |
| CN-1780909-A | nucleotide chain modification method | MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) | 2006-05-31 | — | — | CN | disclosed |
| EP-0910246-A4 | USE OF MUTANT ALKYLTRANSFERASES FOR GENE THERAPY TO PROTECT FROM TOXICITY OF THERAPEUTIC ALKYLATING AGENTS | PENN STATE RES FOUND (US) | 2003-07-02 | — | — | EP | disclosed |
| WO-1999025386-A1 | delta-O6-METHYLGUANINE-DNA METHYLTRANSFERASE GENE TRANSFER FOR O6-BENZYLGUANINE AND (N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA) RESISTANCE | CASE WESTERN RESERVE UNIVERSITY (US) | 1999-05-27 | — | — | WO | disclosed |
| EP-0910246-A1 | USE OF MUTANT ALKYLTRANSFERASES FOR GENE THERAPY TO PROTECT FROM TOXICITY OF THERAPEUTIC ALKYLATING AGENTS | THE PENN STATE RESEARCH FOUNDATION (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997035477-A1 | USE OF MUTANT ALKYLTRANSFERASES FOR GENE THERAPY TO PROTECT FROM TOXICITY OF THERAPEUTIC ALKYLATING AGENTS | THE PENN STATE RESEARCH FOUNDATION (US) | 1997-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022605-A1 | METHODS FOR REDUCING MICROSATELLITE INSTABILITY INDUCED BY CHEMOTHERAPY AND METHODS FOR SCREENING ANTIOXIDANTS THAT SUPPRESS DRUG-INDUCED MICROSATELLITE INSTABILITY WHILE ENHANCING THE CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | MSH2, PCNA, PMS2 | DPP4 4601/4885PNP 2676/4885ADORA2A 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.